Abstract
Obstructive sleep apnea syndrome (OSA) is a highly prevalent breathing disorder in sleep affecting at least 2- 4% of the adult population. A large number of studies have demonstrated that OSA is an independent risk factor of cardiovascular morbidity and mortality. Sleep apnea was shown to be associated with hypertension, ischemic heart disease, stroke, pulmonary hypertension, cardiac arrhythmia, and cardiovascular mortality. The association of OSA with subclinical signs of cardiovascular morbidity such as endothelial dysfunction and vasculature remodeling on the one hand, and with oxidative stress, activation of inflammatory pathways and increased leukocytes/endothelial cells adhesion on the other, implicate that atherogenesis plays a major role in cardiovascular sequela of OSA. Results demonstrating that effective treatment of the syndrome can abort and even reverse the atherogenic process suggest that OSA should be diagnosed and treated as early as possible in order to prevent cardiovascular sequlea.
Keywords: Obstructive sleep apnea, cardiovascular morbidity, nCPAP, hypertension, mortality
Current Pharmaceutical Design
Title: Cardiovascular Morbidity and Mortality in Obstructive Sleep Apnea
Volume: 14 Issue: 32
Author(s): Peretz Lavie and Lena Lavie
Affiliation:
Keywords: Obstructive sleep apnea, cardiovascular morbidity, nCPAP, hypertension, mortality
Abstract: Obstructive sleep apnea syndrome (OSA) is a highly prevalent breathing disorder in sleep affecting at least 2- 4% of the adult population. A large number of studies have demonstrated that OSA is an independent risk factor of cardiovascular morbidity and mortality. Sleep apnea was shown to be associated with hypertension, ischemic heart disease, stroke, pulmonary hypertension, cardiac arrhythmia, and cardiovascular mortality. The association of OSA with subclinical signs of cardiovascular morbidity such as endothelial dysfunction and vasculature remodeling on the one hand, and with oxidative stress, activation of inflammatory pathways and increased leukocytes/endothelial cells adhesion on the other, implicate that atherogenesis plays a major role in cardiovascular sequela of OSA. Results demonstrating that effective treatment of the syndrome can abort and even reverse the atherogenic process suggest that OSA should be diagnosed and treated as early as possible in order to prevent cardiovascular sequlea.
Export Options
About this article
Cite this article as:
Lavie Peretz and Lavie Lena, Cardiovascular Morbidity and Mortality in Obstructive Sleep Apnea, Current Pharmaceutical Design 2008; 14 (32) . https://dx.doi.org/10.2174/138161208786549317
DOI https://dx.doi.org/10.2174/138161208786549317 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Thrombin Activatable Fibrinolysis Inhibitor in Endocrine and Cardiovascular Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Oxidative Stress in Post-Acute Ischemic Stroke Patients after Intensive Neurorehabilitation
Current Neurovascular Research Serum Collagen Markers and Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Balancing the Risks of Thrombosis and Bleeding Following Transcatheter Aortic Valve Implantation: Current State-of-Evidence
Current Pharmaceutical Design Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets Hypoxia Inducible Factor Stabilization As a Novel Strategy to Treat Anemia
Current Medicinal Chemistry Pathophysiological Basis for Anticoagulant and Antithrombotic Therapy in Pulmonary Hypertension
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial [Hot Topic:Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design General Aspects of Metal Toxicity
Current Medicinal Chemistry 3D Printing as a Significant Achievement for Application in Posttraumatic Surgeries - A Literature Review
Current Medical Imaging Asthma-COPD Overlap: A more Simplistic Approach
Current Respiratory Medicine Reviews Aortic Dissection: A Review of the Pathophysiology, Management and Prospective Advances
Current Cardiology Reviews Polypharmacology in a Single Drug: Multitarget Drugs
Current Medicinal Chemistry Editorial [Hot Topic: Cardiovascular Diagnostic Testing: Use and Limits of Biochemical Markers (Executive Editors: Aurelio Leone and Stefano Taddei)]
Current Pharmaceutical Design Adipokines and Myokines: A Pivotal Role in Metabolic and Cardiovascular Disorders
Current Medicinal Chemistry Syntheses of 2,3-Diarylated 2H-Benzo[e][1,2]Thiazine 1,1-Dioxides and their 3,4-Dihydro Derivatives, and Assessment of their Inhibitory Activity Against MCF-7 Breast Cancer Cells
Medicinal Chemistry Propionate: Hypophagic Effects Observed in Animal Models Might be Transposed to the Human Obesity Management
Current Nutrition & Food Science The Role of Chymase in Vascular Remodeling and Tissue Fibrosis
Current Hypertension Reviews Modulation of Gi Proteins in Hypertension: Role of Angiotensin II and Oxidative Stress
Current Cardiology Reviews Mitochondria as a Therapeutic Target for Aging and Neurodegenerative Diseases
Current Alzheimer Research